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Abstract We describe the case of a 39-year-old human
immunodeficiency virus (HIV)-infected man with angio-
graphically documented rapid progression of coronary
artery disease. Over a time course of only 2 months, he
developed high-grade stenosis of the left anterior descend-
ing coronary artery. The risk of myocardial infarction
is increased in patients with HIV infection receiving
antiretroviral therapy. However, the absolute risk is small
and the marked overall benefits of antiretroviral therapy
are evident. Patients receiving HIV protease inhibitors
should be screened for hyperlipidemia, hyperglycemia, and
hypertension. They may be candidates for lipid-lowering
therapies depending on their long-term prognosis and indi-
vidual risk of cardiovascular disease. Care is need because
of possible drug interactions between lipid-lowering drugs
and antiretroviral therapy. Invasive treatment of acute
myocardial infarction does not differ from that in patients
not infected with HIV. The rate of progression of coronary
artery disease and the restenosis rate, however, are often
unexpectedly high in these patients.
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Case report
A 39-year-old man was admitted for elective coronary
angiography because of postinfarctious exercise-induced
atypical chest pain 2 weeks after an acute posterolateral
myocardial infarction (maximum creatine kinase 937U/l).
The myocardial infarction had not been heralded by
symptoms.
The patient was known to have had human immunodefi-
ciency virus (HIV) infection for 14 years, and he received
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highly active antiretroviral drug therapy (HAART) con-
sisting of the protease inhibitor nelfinavir, the non-
nucleoside reverse transcriptase inhibitor nevirapine, and
the nucleoside reverse transcriptase inhibitor stavudine
for 5 years. Moderate arterial hypertension was success-
fully controlled with a -blocker for 1 year. Laboratory
analyses showed untreated dyslipidemia (total cholesterol
6.4mmol/l, high-density lipoprotein cholesterol 0.92mmol/l;
triglycerides 7.1mmol/l). Blood sugar was normal, he was a
non-smoker, and there was no family history of cardiovas-
cular disease.
The coronary angiography showed high-grade stenosis
of the circumflex branch of the left coronary artery (Fig. 1A,
arrow). In addition, an intermediary branch was severely
stenosed. The left anterior descending coronary artery
(LAD) was free of stenosis, as was the right coronary artery
(RCA). The circumflex was successfully stented with a
sirolimus-eluting stent (Fig. 1B). The patient was dismissed
with a prescription including aspirin, clopidogrel, carve-
dilol, lisinopril, and pravastatin. The antiviral triple-drug
regime was not changed.
Two months later, the patient was readmitted because of
worsening exercise-induced chest pain. Coronary angiogra-
phy showed a filiform de novo lesion of the LAD (Fig. 1C,
arrow). The previously implanted stent in the circumflex
artery was open. In addition, the RCA showed several low-
grade lesions, and high-grade stenosis of a posterolateral
branch of the RCA receiving collaterals from the LAD.
Based on the clinical presentation and the angiographic
appearance of the lesion, plaque rupture seemed unlikely.
Instead, the lesion appeared to have rapidly progressed
from a minor plaque. Traditional predictors of rapid plaque
progression such as bifurcation location, plaque irregular-
ity, or presence of a thrombus had not been present ini-
tially.1,2 Whereas it is not uncommon for minor plaques to
progress over subsequent years, the present rapid progres-
sion to a subtotal lesion was unusual.3,4 The LAD was
stented using a sirolimus-eluting stent (Fig. 1D). Lipid-
lowering therapy was optimized by adding ezetimibe to the
statin. The patient remained asymptomatic over the follow-
ing 6 months.
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In conclusion, we are reporting an unusually rapid pro-
gression of atherosclerosis in the coronary artery of an
HIV-infected patient who developed a severe LAD stenosis
within 2 months. This case highlights the importance of
aggressive lipid-lowering strategies in patients with HIV
infection treated with HAART. However, care is needed
because of possible drug interactions between lipid-
lowering drugs and antiretroviral therapy.
Discussion
Metabolic changes associated with HIV infection and
antiretroviral therapy
Human immunodeficiency virus infection itself is associated
with dyslipidemia. Following HIV infection, an early de-
crease in high-density lipoprotein (HDL) cholesterol and
elevations in triglycerides are observed while low-density
lipoprotein (LDL) cholesterol decreases later in the course
of the disease.
HIV patients are at higher risk of developing hyper-
tension at a younger age than the general population.
Predisposing factors for developing hypertension include
vasculitis,5,6 which may also be associated with aneurysms of
the large vessels, such as the carotid and femoral arteries
and the abdominal aorta.7 Acquired glucocorticoid resis-
tance in patients with HIV hypercortisolism promotes the
development of hypertension.8
Besides reverse transcriptase inhibitors, HIV protease
inhibitors are key components of antiviral therapy. How-
ever, they can cause hyperlipidemia, hyperglycemia, and
central obesity.9,10 Cardiovascular risk is increased by this
metabolic derangement and premature atherosclerotic vas-
cular disease may be the consequence. Indeed, insulin resis-
tance occurs in as many as 25%–60% of patients treated
with protease inhibitors.11–13 Protease inhibitors lead to
typical alterations in lipid metabolism commonly associated
with insulin resistance, i.e., decreased HDL, increased LDL
cholesterol and triglycerides, and hyperinsulinemia. As a
consequence, there is reduced uptake of serum lipids by
fat cells, increased lipolysis in the subcutaneous adipose
tissue, and increased production of lipids by hepatocytes.
Increased tumor necrosis factor α (TNFα) induces eleva-
tion of free fatty acids and insulin resistance. Decreased
perosixome-proliferator activated receptor (PPARγ)
function causes increased subcutaneous adipocyte and mac-
rophage apoptosis, as well as reduced promotion of choles-
terol efflux via ATP-binding cassette transporter (ABCA1).
Therefore, hyperinsulinemia is not necessarily a feature of
this derangement; dyslipidemia also occurs without insulin
resistance.
In addition, protease inhibitors such as ritonavir,
indinavir, and amprenavir upregulate CD36, a scavenger
receptor that mediates cholesterol uptake in macrophages.14
Fig. 1A–D. Coronary
angiography. A High-grade
stenosis of the circumflex branch
(Cx) of the left coronary artery
(arrow). In addition, an
intermediary branch (IB) is
severely stenosed. The left
anterior descending coronary
artery (LAD) is free of stenosis.
B The circumflex coronary
artery was successfully stented
with a sirolimus-eluting stent.
C Two months later, coronary
angiography shows a filiform de
novo lesion of the LAD (arrow).
The previously implanted stent
in the circumflex artery is open.
D The LAD stented with a
sirolimus-eluting stent
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Highly active antiretroviral drug therapy thus directly pro-
motes atherosclerosis independently from the metabolic
changes described above.
Mitochondrial dysfunction due to nucleoside-analogue
reverse transcriptase inhibitors such as stavudine may also
contribute to metabolic changes. This class of antiretroviral
drugs, often prescribed in combination with protease inhibi-
tors, may cause dyslipidemia itself.
Premature coronary artery disease in patients with
HIV infection
Premature coronary artery disease in HIV-infected patients
treated with HAART has been postulated in retrospective
analyses of large-cohort studies.15–20 In a French cohort of
700 HIV-infected patients treated with HAART, 9 patients
(1.3%) suffered acute coronary events after an average
treatment duration of 18 months.19 Patients with an event
were young men (average age, 40 years) infected with the
virus for an average of 7 years. In the HIV outpatient study
(HOPS) that included 5672 patients with HIV-1 infection,
patients taking protease inhibitors were at significantly in-
creased risk for myocardial infarction (1.4 vs 0.5 cases per
1000 person-years; hazard ratio 6.5, 95% confidence inter-
val [CI] 0.9–47.8, adjusted for cardiovascular risk factors).16
Although occurring infrequently, these events are of clinical
and epidemiological significance considering the young
age of these patients. In the large DAD (Data collection
on Adverse events of anti-HIV Drugs) study comprising
23468 HIV-infected patients, 27% of protease inhibitor-
treated patients had hypercholesterolemia (total choles-
terol 6.2mmol/l), and 27% showed low HDL cholesterol
(0.9mmol/l).21 Over 36199 person-years, 126 patients
developed a myocardial infarction. The incidence of myo-
cardial infarction increased with longer exposure to combi-
nation antiretroviral therapy with an adjusted relative risk
per year of exposure of 1.3 (95% CI 1.1–1.4; P  0.001).
combination antiretroviral therapy was independently asso-
ciated with a 26% relative increase in the rate of myocardial
infarction per year of exposure over the first 4–6 years of
use.20
In summary, the risk of myocardial infarction is in-
creased in patients with HIV infection receiving HAART.
However, the absolute risk is small and the marked overall
benefits of antiretroviral therapy are evident. Thus, indi-
vidual cardiovascular risk factors should be assessed and
treated.
Treatment strategies
Although the risk for atherosclerotic vascular disease is
increased, the benefits of antiretroviral therapy outweight
the risk.22 Patients receiving HIV protease inhibitors should
be screened for hyperlipidemia, hyperglycemia, and hyper-
tension. They may be candidates for lipid-lowering thera-
pies depending on their long-term prognosis and individual
risk of cardiovascular disease. Invasive treatment of acute
myocardial infarction does not differ from that in patients
not infected with HIV.23 The restenosis rate, however, is
unexpectedly high in these patients.24
When initiating lipid-lowering therapy, interaction
between statins and HIV protease inhibitors affecting
cytochrome P450 (CYP) function must be considered.
Simvastatin, atorvastatin, and lovastatin – but not pravas-
tatin and fluvastatin – are metabolized by CYP3A4 and thus
should be avoided in persons taking protease inhibitors
such as ritonavir and saquinavir. Pravastatin does not alter
nelfinavir pharmacokinetics, and thus appears to be safe
for concomitant use. In general, starting statin therapy using
a low initial dose is recommended. In patients with protease
inhibitor-associated hypertriglyceridemia, the use of a
fibrate such as gemfibrozil does not normalize triglyceride
levels.25 Ezetimibe may be combined with a statin to mini-
mize its dose and potential drug interactions. However,
there are no studies investigating the safety and efficacy of
this combination in patients with HIV infection.
In patients with lipodystrophy, switching protease inhibi-
tors to reverse transcriptase inhibitors may be considered.
However, in a randomized trial in patients with peripheral
lipoatrophy, switching from HIV protease inhibitor therapy
to abacavir, nevirapine, adefovir, or hydroxyurea led to
improved lipids and less intra-abdominal fat, but also to less
peripheral fat, and had a minimal effect on insulin resis-
tance. Virological control in these patients was unaffected,
despite frequent-switch drug cessations.26 Another study re-
ports on a trend towards worse virological control after
switching from protease inhibitors to nevirapine, efavirenz,
or abacavir.27 Abacavir may cause a hypersensitivity reac-
tion in about 10% of patients, with the need to stop the drug
indefinitely. Switching nucleoside analogues to a less toxic
reverse transcriptase inhibitor such as abacavir only causes
a modest increase in limb fat.28
In conclusion, the risk of myocardial infarction is in-
creased in patients with HIV infection receiving HAART.
However, the absolute risk is small and the marked overall
benefits of antiretroviral therapy are evident. Patients
receiving HIV protease inhibitors should be screened for
hyperlipidemia, hyperglycemia, and hypertension. They
may be candidates for lipid-lowering therapies depending
on their long-term prognosis and individual risk of cardio-
vascular disease. Invasive treatment of acute myocardial
infarction does not differ from that in patients not
infected with HIV. The rate of progression of coronary
artery disease and the restenosis rate, however, are often
unexpectedly high in these patients.
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